Symetis touts positive findings for its Acurate TA TAVI system

April 4, 2013 by Arezu Sarvestani

Swiss device maker Symetis reports promising 30-day outcomes from its Acurate TA transcatheter aortic valve implantation postmarket registry.

Symetis logo

Swiss medical device maker Symetis released 30-day registry findings for its 2nd-generation transcatheter aortic valve implantation systems, touting high procedural success rates and minimal valve leakage.

Results from the SAVI postmarket registry highlighted findings from the 1st 250 patients implanted with Symetis' Acurate TA TAVI system, which won European regulatory approval in September 2011.

Sign up to get our free newsletters delivered right to your inbox.

Symetis reported a 98% procedural success rate as well as "a very good safety profile and minimal PV leak rate," according to a press release. All-cause mortality at 30 days was 6.8%, a rate that the company touted as one of the lowest in reported registries for other TAVI systems.

"The Acurate TA has proven to be the most user-friendly and patient-effective transapical TAVI today on the market," Symetis clinical & regulatory affairs vice president said in prepared remarks. "Our TA R&D pipeline will further raise this new standard and expand the TA indication."